Jazz music (jazz) highlights growth at the Goldman Sachs Healthcare Conference

Jazz Pharmaceuticals PLC (NASDAQ:jazz) He is One of the most 7 shares of less than its value is less than its value for purchase, according to analysts. On June 11, the company presented at the Goldman SACHS 46 global health care conference, defining strategic growth initiatives and recognized various challenges.

As soon as hemp plants grow in an external facility, they symbolize the product of the cannabis company.

According to the presentation, Jazz Pharmaceuticals has reported strong growth in its neuroscience, especially with XyWav (for sleep disorders such as scourge and unknown hyperactivity) and Epidiolex (for epilepsy). These products showed “strong growth” in the first quarter of 2025. The low sodium content of Xywav and flexible doses were highlighted as the main market benefits.

The company detailed that it is working to expand the oncology portfolio and pipeline, which now represents more than half of its revenues, 2024, an increase of 26 % in 2018. The main oncology initiatives include Zanidatamab (ZiIHERA), Zepzelca (Lurbinishedin), and Subzelca (formerly JZP-351) and Dordavabril (from Chimeriredin).

The company stated that beyond the products that are marketed, it enhances its pipeline by launching upcoming products and expected regulatory decisions to advance growth in the future. This includes Orexin (JZP-441 experiments monitored for cardiovascular effects) and Prasinezumab in Europe.

Jazz Pharmaceuticals PLC (Nasdaq: Jazz) expanded its mark to the cannabis sector with the acquisition of GW Pharmaceuticals. Thus, it develops and markets approved drugs from the FDA that contain hemp materials, especially CBD, to treat serious diseases.

Although we acknowledge the potential of jazz as an investment, we believe that some of the artificial intelligence shares provide greater potential in the upward direction and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 15 successful cross companies and 2025 return and 12 The best consumer goods are buying quietly.

Detection: Nothing. This article was originally published in A monkey from the inside.